(HROW) Harrow Health, Inc. Business Model Canvas Research

Ophthalmology providers are Harrow Health, Inc.’s core external partners because eye-care prescribers and surgical specialists drive use of ImprimisRx compounded therapies and DEXYCU in cataract surgery. This network matters at scale: DEXYCU is used by ophthalmic surgeons, while Harrow’s specialty focus depends on repeat prescribing and procedure-linked adoption.

• Eye-care prescribers drive demand.
• Surgical specialists support DEXYCU use.
• Provider ties shape Harrow’s specialty model.

Harrow Health, Inc. depends on hospital, outpatient, and office-based procedure sites to reach Melt’s core use cases, so access to the right care setting matters as much as the product itself. Manufacturing, compounding, and distribution partners then turn specialty ophthalmic assets into wider commercial reach and steadier availability.

• Procedure sites drive use.
• Supply partners keep product flowing.
• Network reach supports commercialization.

Harrow Health, Inc. manages equity stakes in Surface, Melt, and Eton as a live portfolio task, not a passive one. In FY2025, this tied Harrow to both clinical-stage and commercial-stage value drivers, with Eton already public and Surface and Melt still development-stage, so the mix spreads risk across different milestones.

• Tracks three equity holdings
• Blends clinical and commercial exposure
• Depends on milestone-driven value shifts

Harrow Health, Inc. treats royalty administration as a separate key activity because it holds royalty rights in 4 investigational drug candidates and must track milestones, sales, and payments closely. This creates a non-operating income stream that can add upside without adding core product cost.

• Monitors 4 royalty-backed candidates
• Tracks milestone and sales payments
• Adds non-operating income to Harrow

The value comes from turning drug progress into cash receipts, so execution here matters even when Harrow is not the seller of the drug.

Harrow Health, Inc. holds royalty interests in 4 investigational drug candidates, a compact set of high-upside intangible assets that can turn into recurring revenue if even one program reaches approval and sales. In its latest filings, these rights sit alongside other royalty assets and remain valuable because upside is tied to pipeline progress, not near-term product sales.

• 4 royalty-bearing investigational candidates
• Intangible asset with milestone-linked upside
• Value grows if trials and approvals succeed

Harrow Health, Inc.’s specialized ophthalmic expertise is a core resource because the company is built around eye-care products, which sharpens product positioning, partner trust, and market focus. Founded in 2006 and renamed in 2018, Harrow uses this narrow clinical focus to stay relevant in ophthalmology instead of spreading across broader pharma markets.

• Built around ophthalmic solutions
• Supports partner relationships
• Improves market focus
• Incorporated in 2006
• Renamed in 2018

Harrow Health, Inc. gains portfolio exposure across Surface, Melt, and Eton, so its value proposition is not tied to one asset. That spreads development and commercialization risk and gives Harrow multiple shots at upside as each equity stake advances on its own timeline.

• Three pipeline bets, not one
• Lower single-asset dependence
• Multiple paths to monetization

Harrow Health, Inc. holds royalty interests in 4 investigational drug candidates, so it can capture upside if any asset succeeds without funding full manufacturing. That creates a more asset-light income stream and spreads risk across multiple programs instead of betting on one drug.

• 4 royalty-backed drug candidates

• No direct manufacturing burden

• Diversified, asset-light upside

Harrow Health keeps active oversight of its equity stakes and royalty interests, especially with Surface, Melt, and Eton, because the links are both strategic and financial. That oversight matters when non-operating investments can still affect cash flow and partner alignment.

• Strategic partner fit
• Royalty cash flow watch
• Equity value tracking

Harrow Health, Inc. has run since 2006 and adopted its current name in 2018, so its customer ties in eye care reflect long continuity in a narrow specialty. In a focused market, that kind of steady presence helps build trust with prescribers and patients who want consistent access and support.

• 2006 operating history
• 2018 name change
• Narrow specialty focus
• Trust built over time

Harrow Health, Inc. uses equity stakes and royalty interests as indirect monetization channels: value rises when partners hit development milestones, launch products, and expand sales. In 2025–2026, this model tied Harrow Health’s cash flow more to partner execution than to direct product volume, so the channel stays small in day-to-day sales but large in upside.

• Partner milestones drive payouts
• Royalties scale with sales
• Equity gains track development success

Harrow Health, Inc. sells in specialty pharmaceutical and ophthalmic channels where reach depends on tight distribution and strong prescriber awareness. This model fits niche commercialization, because a small pool of eye-care prescribers can drive outsized demand.

Channel strength comes from targeted access, not broad retail scale, so education and physician pull matter most.

• Focused ophthalmology distribution
• High prescriber awareness needed
• Niche products support efficient sell-through

Office-based procedure sites are a core Melt treatment setting because they fit efficient specialty care delivery and improve access to procedural medicine. For Harrow Health, Inc., this segment matters most where quick turnaround, lower site complexity, and same-day treatment flow support wider use in 2025-2026 care models.

• Office setting matches Melt's target use case.
• Supports faster specialty care delivery.
• Expands procedural medicine access.

Surface, Melt, and Eton are not end customers; they are clinical-stage or commercial pharma counterparts that sit in Harrow Health, Inc.’s value chain. Harrow’s upside comes from equity and royalty interests tied to their progress, so each partner’s data, approvals, and sales directly affect Harrow’s cash flow mix.

• Counterparties, not buyers
• Value tied to pipeline progress
• Royalties add investment-style upside

Harrow Health, Inc. carries public-company overhead for management, SEC reporting, legal, finance, and admin support, and that cost base feeds both operating and investment activity. In its latest filing, general and administrative expense stayed a key corporate line item, showing the price of running a listed healthcare platform.

• Funds management and reporting
• Supports operating and investment work
• Public-company overhead stays material

Managing Harrow Health, Inc. equity stakes and royalty interests adds steady admin cost because each asset needs payment tracking, contract checks, and counterparty review. In fiscal 2025, this kind of oversight sat inside a wider cost base tied to portfolio monitoring, legal work, and finance control across multiple revenue streams.

• Track each asset and payer
• Review royalty terms often
• Raise admin and legal overhead

Harrow Health, Inc. holds royalty interests in 4 investigational drug candidates, so any future approval and sales can turn into non-operating royalty income for the company. This stream is still binary, but it can add high-margin cash flow if even one asset reaches market.

• 4 royalty-backed candidates
• Revenue depends on approvals
• Non-operating, high-margin income

Harrow Health, Inc. uses a mix of operating assets and investments to create partnering upside, so value can show up when clinical-stage assets move closer to approval and commercialization. In 2025, that model broadened revenue beyond direct product sales by adding potential milestones, royalties, and deal income from pipeline monetization.

• Partnering lifts revenue beyond product sales.
• Clinical progress can trigger milestone income.
• Royalties can scale without heavy selling cost.